Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

The U.S. stock market sank from record heights as Wall Street sifted through mixed developments on everything from the ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.

An astonishing fact about the GLP-1 meds that are helping millions lose weight: Tirzepatide, the active ingredient in ...

These growth stocks are highly profitable and evolving in their respective industries. Eli Lilly is famed for its weight-loss medications, but it is more than just a GLP-1 play. MercadoLibre is a ...

Scripps Research in La Jolla announce a new clinical trial that will assess the effectiveness of using drugs approved for ...

Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

An expert said weight loss drugs might help people see faster results, which can give them encouragement to continue. But he ...

Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom.

Merck and Eisai announced termination of a phase III trial of pembrolizumab plus lenvatinib (Lenvima) and transarterial chemoembolization (TACE) for unresectable liver cancer after an interim analysis ...